{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.02","upperLimit":"0.05","value":"0.01"},{"groupId":"OG001","lowerLimit":"-0.01","upperLimit":"0.05","value":"0.02"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"0.05","value":"0.02"},{"groupId":"OG003","lowerLimit":"-0.01","upperLimit":"0.04","value":"0.01"},{"groupId":"OG004","lowerLimit":"-0.01","upperLimit":"0.05","value":"0.02"},{"groupId":"OG005","lowerLimit":"-0.02","upperLimit":"0.04","value":"0.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.02","upperLimit":"0.09","value":"0.06"},{"groupId":"OG001","lowerLimit":"-0.02","upperLimit":"0.05","value":"0.01"},{"groupId":"OG002","lowerLimit":"-0.01","upperLimit":"0.04","value":"0.01"},{"groupId":"OG003","lowerLimit":"-0.02","upperLimit":"0.03","value":"0.01"},{"groupId":"OG004","lowerLimit":"-0.04","upperLimit":"0.02","value":"-0.01"},{"groupId":"OG005","lowerLimit":"-0.04","upperLimit":"0.03","value":"-0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.01","upperLimit":"0.08","value":"0.04"},{"groupId":"OG001","lowerLimit":"-0.00","upperLimit":"0.06","value":"0.03"},{"groupId":"OG002","lowerLimit":"-0.01","upperLimit":"0.04","value":"0.02"},{"groupId":"OG003","lowerLimit":"-0.04","upperLimit":"0.01","value":"-0.01"},{"groupId":"OG004","lowerLimit":"-0.05","upperLimit":"0.01","value":"-0.02"},{"groupId":"OG005","lowerLimit":"-0.05","upperLimit":"0.02","value":"-0.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.01","upperLimit":"0.06","value":"0.02"},{"groupId":"OG001","lowerLimit":"-0.00","upperLimit":"0.07","value":"0.03"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"0.05","value":"0.03"},{"groupId":"OG003","lowerLimit":"-0.04","upperLimit":"0.02","value":"-0.01"},{"groupId":"OG004","lowerLimit":"-0.05","upperLimit":"0.01","value":"-0.02"},{"groupId":"OG005","lowerLimit":"-0.01","upperLimit":"0.05","value":"0.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.01","upperLimit":"0.06","value":"0.03"},{"groupId":"OG001","lowerLimit":"-0.00","upperLimit":"0.07","value":"0.03"},{"groupId":"OG002","lowerLimit":"0.01","upperLimit":"0.06","value":"0.03"},{"groupId":"OG003","lowerLimit":"-0.02","upperLimit":"0.04","value":"0.01"},{"groupId":"OG004","lowerLimit":"-0.03","upperLimit":"0.03","value":"-0.00"},{"groupId":"OG005","lowerLimit":"-0.03","upperLimit":"0.04","value":"0.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.01","upperLimit":"0.06","value":"0.03"},{"groupId":"OG001","lowerLimit":"-0.02","upperLimit":"0.06","value":"0.02"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"0.05","value":"0.03"},{"groupId":"OG003","lowerLimit":"-0.02","upperLimit":"0.03","value":"0.01"},{"groupId":"OG004","lowerLimit":"-0.04","upperLimit":"0.02","value":"-0.01"},{"groupId":"OG005","lowerLimit":"-0.02","upperLimit":"0.05","value":"0.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.03","upperLimit":"0.11","value":"0.07"},{"groupId":"OG001","lowerLimit":"-0.00","upperLimit":"0.07","value":"0.03"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"0.05","value":"0.03"},{"groupId":"OG003","lowerLimit":"-0.01","upperLimit":"0.05","value":"0.02"},{"groupId":"OG004","lowerLimit":"-0.05","upperLimit":"0.02","value":"-0.01"},{"groupId":"OG005","lowerLimit":"-0.02","upperLimit":"0.05","value":"0.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 10 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.01","upperLimit":"0.08","value":"0.05"},{"groupId":"OG001","lowerLimit":"-0.03","upperLimit":"0.05","value":"0.01"},{"groupId":"OG002","lowerLimit":"-0.01","upperLimit":"0.05","value":"0.02"},{"groupId":"OG003","lowerLimit":"-0.02","upperLimit":"0.04","value":"0.01"},{"groupId":"OG004","lowerLimit":"-0.04","upperLimit":"0.03","value":"-0.00"},{"groupId":"OG005","lowerLimit":"-0.01","upperLimit":"0.07","value":"0.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.05","upperLimit":"0.05","value":"0.00"},{"groupId":"OG001","lowerLimit":"-0.01","upperLimit":"0.07","value":"0.03"},{"groupId":"OG002","lowerLimit":"-0.01","upperLimit":"0.07","value":"0.03"},{"groupId":"OG003","lowerLimit":"-0.04","upperLimit":"0.03","value":"-0.00"},{"groupId":"OG004","lowerLimit":"-0.04","upperLimit":"0.06","value":"0.01"},{"groupId":"OG005","lowerLimit":"-0.03","upperLimit":"0.07","value":"0.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 14 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.03","upperLimit":"0.08","value":"0.03"},{"groupId":"OG001","lowerLimit":"-0.01","upperLimit":"0.10","value":"0.05"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"0.09","value":"0.05"},{"groupId":"OG003","lowerLimit":"-0.05","upperLimit":"0.02","value":"-0.02"},{"groupId":"OG004","lowerLimit":"-0.10","upperLimit":"0.08","value":"-0.01"},{"groupId":"OG005","lowerLimit":"-0.03","upperLimit":"0.08","value":"0.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.06","upperLimit":"0.09","value":"0.02"},{"groupId":"OG001","lowerLimit":"-0.04","upperLimit":"0.07","value":"0.01"},{"groupId":"OG002","lowerLimit":"0.02","upperLimit":"0.11","value":"0.06"},{"groupId":"OG003","lowerLimit":"-0.06","upperLimit":"0.03","value":"-0.02"},{"groupId":"OG004","lowerLimit":"-0.30","upperLimit":"-0.06","value":"-0.18"},{"groupId":"OG005","lowerLimit":"-0.01","upperLimit":"0.10","value":"0.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 18 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.15","upperLimit":"0.03","value":"-0.06"},{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"0.13","value":"0.07"},{"groupId":"OG002","lowerLimit":"-0.05","upperLimit":"0.08","value":"0.02"},{"groupId":"OG003","lowerLimit":"-0.06","upperLimit":"0.05","value":"-0.01"},{"groupId":"OG005","lowerLimit":"-0.04","upperLimit":"0.09","value":"0.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.07","upperLimit":"0.11","value":"0.02"},{"groupId":"OG001","lowerLimit":"-0.02","upperLimit":"0.12","value":"0.05"},{"groupId":"OG002","lowerLimit":"-0.03","upperLimit":"0.11","value":"0.04"},{"groupId":"OG003","lowerLimit":"-0.14","upperLimit":"0.00","value":"-0.07"},{"groupId":"OG005","lowerLimit":"-0.04","upperLimit":"0.11","value":"0.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"Cycle 22 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.03","upperLimit":"0.21","value":"0.09"},{"groupId":"OG003","lowerLimit":"-0.11","upperLimit":"0.13","value":"0.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}],"units":"Participants"}],"title":"Cycle 24 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.10","upperLimit":"0.05","value":"-0.03"},{"groupId":"OG001","lowerLimit":"-0.05","upperLimit":"0.11","value":"0.03"},{"groupId":"OG002","lowerLimit":"-0.02","upperLimit":"0.07","value":"0.03"},{"groupId":"OG003","lowerLimit":"-0.04","upperLimit":"0.05","value":"0.01"},{"groupId":"OG004","lowerLimit":"-0.08","upperLimit":"0.02","value":"-0.03"},{"groupId":"OG005","lowerLimit":"-0.05","upperLimit":"0.08","value":"0.02"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"title":"End of treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"38"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"description":"The One Back Test is a measure of working memory and uses a well validated n back paradigm with playing cards. In this task, the on-screen instructions ask: \"Is the previous card the same?\". A playing card is presented in the center of the screen. The participant must decide whether the card is the same as the previous card. If it is the same the participant should press \"Yes\", and if not press \"No\". The participant is encouraged to work as quickly and accurately as possible. The speed and accuracy of each response are recorded, mean of the log10 transformed reaction times for correct responses is used to demonstrate speed of performance, and the arcsine transformation of the square root of the proportion of correct responses is used to demonstrate accuracy. Lower values of least square mean change from baseline indicate performance decline. Upper limit of 95% confidence interval of -0.00 or lower indicate statistically significant decline of performance over baseline at that cycle.","dispersionType":"95% Confidence Interval","groups":[{"description":"Treatment-naïve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG000","title":"EXP-1 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG001","title":"EXP-2 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG002","title":"EXP-3 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG003","title":"EXP-4 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG004","title":"EXP-5 (Phase 2)"},{"description":"Participants with advanced ROS1-positive NSCLC who were treatment naïve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG005","title":"EXP-6 (Phase 2)"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"PRO evaluable analysis set included all enrolled participants who received study treatment, had a baseline test assessment and at least 1 on-study test assessment. Here, 'Number Analyzed' signifies participants evaluable for specified row.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of Cycles 2-5, Day 1 of every other cycle from Cycle 6, and end of treatment (up to 3 years)","title":"Change From Baseline in Total Scores for One Back Test (Cognitive Function Assessment) (Phase 2)","type":"SECONDARY","unitOfMeasure":"Units on a scale"}